Dietary Intervention Prevents Dyslipidemia Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Individuals

被引:46
|
作者
Lazzaretti, Rosmeri K. [1 ]
Kuhmmer, Regina [1 ]
Sprinz, Eduardo [2 ,3 ]
Polanczyk, Carisi A. [1 ,3 ]
Ribeiro, Jorge P. [1 ,3 ]
机构
[1] Hosp Clinicas Porto Alegre, Div Cardiol, BR-90035007 Porto Alegre, RS, Brazil
[2] Hosp Clinicas Porto Alegre, Div Internal Med, Porto Alegre, RS, Brazil
[3] Univ Fed Rio Grande do Sul, Fac Med, Dept Med, Porto Alegre, RS, Brazil
关键词
AIDS; cholesterol; nutrition; HIV-INFECTED PATIENTS; PROTEASE INHIBITOR; CHOLESTEROL; AIDS; MANAGEMENT; TRIALS; ADULTS; LIPIDS; RECOMMENDATIONS; LIPODYSTROPHY;
D O I
10.1016/j.jacc.2011.11.038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The purpose of this study was to evaluate the efficacy of dietary intervention on blood lipids of human immunodeficiency virus (HIV)-1-infected patients who are started on highly active antiretroviral therapy (HAART). Background Current guidelines recommend diet as first-step intervention for HIV-1-infected individuals with HAART-related dyslipidemia, but there is no evidence from randomized trials to support this recommendation. Methods Eighty-three HIV-1-infected patients, naive from HAART, were randomly assigned to HAART with dietary intervention (diet group, n = 43) or HAART without dietary intervention (control group, n = 40) for 12 months. Diet, according to the National Cholesterol Education Program, was given every 3 months. Before and after intervention, 24-h food records and lipid profile were obtained. Data were analyzed by intention to treat, using mixed-effects models. Results Diet resulted in reduction of percentage of fat intake (from 31 +/- 7% to 21 +/- 3% of calories), while controls presented no change in percentage of fat intake. Plasma cholesterol (from 151 +/- 29 mg/dl to 190 +/- 33 mg/dl) and low-density lipoprotein cholesterol (from 85 +/- 24 mg/dl to 106 +/- 31 mg/dl) increased in the control group and were unchanged in the diet group. Plasma triglycerides were reduced by diet (from 135 +/- 67 mg/dl to 101 +/- 42 mg/dl) and increased in the control group (from 134 +/- 70 mg/dl to 160 +/- 76 mg/dl). After 1-year follow-up, 21% of patients who received diet had lipid profile compatible with dyslipidemia compared with 68% (p < 0.001) of controls. Conclusions Among HIV-1-positive individuals naive of previous treatment, diet prevents dyslipidemia associated with HAART. (Effect of Nutritional Intervention on the Lipid Profile of HIV-Positive Patients Who Start HAART: a Randomized Trial; NCT00429845) (J Am Coll Cardiol 2012;59:979-88) (C) 2012 by the American College of Cardiology Foundation
引用
收藏
页码:979 / 988
页数:10
相关论文
共 50 条
  • [41] Physical Fitness in Children Infected with the Human Immunodeficiency Virus: Associations with Highly Active Antiretroviral Therapy
    Somarriba, Gabriel
    Lopez-Mitnik, Gabriela
    Ludwig, David A.
    Neri, Daniela
    Schaefer, Natasha
    Lipshultz, Steven E.
    Scott, Gwendolyn B.
    Miller, Tracie L.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (01) : 112 - 120
  • [42] Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy
    Hartman, Karin
    Verweel, Gwenda
    de Groot, Ronald
    Hartwig, Nico G.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2006, 25 (05) : 427 - 431
  • [43] Oral manifestations in human immunodeficiency virus infected children in highly active antiretroviral therapy era
    Pinheiro, Raquel dos Santos
    Franca, Talita Tenorio
    Beder Ribeiro, Camila Maria
    Leao, Jair Carneiro
    Ribeiro de Souza, Ivete Pomarico
    Castro, Gloria Fernanda
    [J]. JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2009, 38 (08) : 613 - 622
  • [44] Highly Active Antiretroviral Therapy-Associated Ptosis in Patients With Human Immunodeficiency Virus
    Silkiss, Rona Z.
    Lee, Han
    Ray, Vincent L. Gills
    [J]. ARCHIVES OF OPHTHALMOLOGY, 2009, 127 (03) : 345 - 346
  • [45] Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy
    Wanke, CA
    Silva, M
    Knox, TA
    Forrester, J
    Speigelman, D
    Gorbach, SL
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 31 (03) : 803 - 805
  • [46] Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy
    Subramaniam, KS
    Segal, R
    Lyles, RH
    Rodriguez-Barradas, MC
    Pirofski, LA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (05): : 758 - 768
  • [47] Temporary seronegativity in a human immunodeficiency virus type 1-infected man
    Zaaijer, HL
    Bloemer, MH
    Lelie, PN
    [J]. JOURNAL OF MEDICAL VIROLOGY, 1997, 51 (01) : 80 - 82
  • [48] Cytomegalovirus infection in human immunodeficiency virus type 1-infected children
    Chandwani, S
    Kaul, A
    Bebenroth, D
    Kim, M
    DiJohn, D
    Fidelia, A
    Hassel, A
    Borkowsky, W
    Krasinski, K
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (04) : 310 - 314
  • [49] Natural history of hyperlactataemia in human immunodeficiency virus-1-infected patients during highly active antiretroviral therapy
    Huynh, TK
    Lüttichau, HR
    Roge, BT
    Gerstoft, J
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2003, 35 (01) : 62 - 66
  • [50] Causes of mortality among patients infected with the human immunodeficiency virus in the era of highly active antiretroviral therapy
    Camino, X
    Iribarren, JA
    Arrizabalaga, J
    Rodríguez, F
    von Wichmann, MA
    [J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2001, 19 (02): : 85 - 86